Budget-Impact Analysis of Health Care Interventions : A Practical Guide.

Intro -- Author Contributions -- Foreword -- Preface -- Abbreviations -- Contents -- Chapter 1: Introduction to Budget-Impact Analysis -- 1.1 What Is Budget-Impact Analysis? -- 1.2 Budget-Impact Analyses Compared with Cost-­Effectiveness Analyses -- 1.3 Uses of Budget-Impact Analyses -- 1.4 Guidelines for Budget-Impact Analyses -- 1.5 Overview of Chapters in This Book -- Exercises -- References -- Chapter 2: Determining the Analytic Framework -- 2.1 Eligible Population in Jurisdiction -- 2.1.1 Impact of Positioning of the New Drug Within the Current Treatment Pathway on Eligible Population Size -- 2.1.2 Impact of Regulatory Approval on Eligible Population Size -- 2.1.3 Impact of Reimbursement Decisions on Eligible Population Size -- 2.1.4 Impact of New Drug Attributes on Initial Population Size -- 2.1.5 Impact of New Drug Attributes on Population Size Over Model Time Horizon -- 2.2 Budget Holder Time Horizon -- 2.3 Potential Use of the New Drug Within the Treatment Mix -- 2.4 Budget Holder Cost Perspective -- 2.4.1 Service Delivery Cost Versus Reimbursement Rate -- 2.4.2 Fixed Versus Variable Costs -- 2.4.3 Cost Categories of Interest -- 2.5 Compilation of Analytic Framework -- Exercises -- References -- Chapter 3: Estimating the Diagnosed, Treated, and Eligible Population -- 3.1 Incident and Prevalent Populations -- 3.2 Estimating the Eligible Population Size -- 3.3 Data for Identifying the Eligible Population -- 3.4 Estimating Population Size by Subgroup -- 3.5 Changing Size of the Eligible Population Over the Analysis Time Horizon -- 3.5.1 Changing Population Size Regardless of Introduction of the New Drug -- 3.5.2 Changing Population Size and Condition Severity Mix due to the Introduction of the New Drug -- 3.6 Including Catch-Up Effects for the Prevalent Population.

3.7 Which Eligible Population Should We Include in the Budget-Impact Analysis? -- Exercises -- References -- Chapter 4: Estimating the Treatment Mix -- 4.1 Treatment Shares Without the New Drug in the Treatment Mix -- 4.2 Treatment Shares with the New Drug in the Treatment Mix -- 4.3 Which Treatment Shares Should We Include in the Budget-Impact Analysis? -- Exercises -- Reference -- Chapter 5: Estimating Treatment-Related Costs -- 5.1 Costs for Drug Acquisition -- 5.1.1 Co-payments and Coinsurance -- 5.1.2 Dispensing Fees -- 5.1.3 Dose Levels -- 5.1.4 Duration of Treatment -- 5.2 Costs for Administering the Drug -- 5.3 Costs for Diagnostic Tests to Determine Eligibility for the Drug -- 5.4 Costs for Monitoring the Drug for Safety and Efficacy -- 5.5 Costs for Treating Side Effects Associated with the Drug -- 5.6 Accounting for Differing Treatment Costs in the First and Subsequent Treatment Years -- 5.7 Accounting for Other Treatment Costs -- 5.8 Estimating Resource Use Changes with the New Drug -- Exercises -- References -- Chapter 6: Estimating Condition-Related Costs -- 6.1 Why the New Drug Might Change Condition-Related Costs -- 6.2 Estimating Changes in Condition-Related Costs for Incident Populations -- 6.2.1 Acute Conditions or Chronic Conditions Where Changes Occur Almost Immediately -- 6.2.2 Chronic Conditions Where Changes Occur Beyond the Budget-Impact Analysis Time Horizon -- 6.2.3 Chronic Conditions Where Changes Occur Gradually Within the Budget-Impact Analysis Time Horizon -- 6.3 Estimating Changes in Condition-Related Costs for Prevalent Populations -- 6.4 Estimating Changes in Health Outcomes and Resource Use with the New Drug -- Exercises -- References -- Chapter 7: The Computing Framework and Calculations -- 7.1 Budget-Impact Calculations -- 7.2 Static Versus Dynamic Approach.

7.3 Examples of Static and Dynamic Budget-Impact Calculations -- 7.3.1 Static Approach -- 7.3.2 Dynamic Approach -- 7.4 Computing Framework for Combined Cost-Effectiveness and Budget-Impact Model -- Exercises -- References -- Chapter 8: Uncertainty Analysis -- 8.1 Sources of Uncertainty -- 8.2 Analyses for Plan-Specific Parameters and Assumptions Known with Certainty -- 8.3 Analyses for Uncertain Input Parameter Values -- 8.4 Probabilistic Sensitivity Analysis? -- Exercises -- References -- Chapter 9: Validation -- 9.1 Introduction to Validation of Budget Impact Analyses -- 9.2 Establishing Face Validity -- 9.3 Establishing Internal Validity -- 9.4 Establishing External Validity -- Exercises -- References -- Chapter 10: Software and Computer Interface -- 10.1 Software -- 10.2 User Interface -- 10.3 Sample User Interface -- Exercises -- Inputs -- Results -- Chapter 11: Reporting Budget-Impact Analyses -- 11.1 Introduction to Reporting Economic Evaluations -- 11.2 Reporting the Budget-Impact Analysis -- 11.2.1 Model Structure Description -- 11.2.2 Structural Assumptions -- 11.2.3 Input Parameters and Their Values -- 11.2.4 Reporting the Base-Case Budget Impact -- 11.2.5 Reporting the Scenario and Sensitivity Analyses -- 11.2.6 Reporting Model Validation -- 11.2.7 Reporting Other Population Outcomes -- 11.2.8 Reporting the Results of a Combined Cost-Effectiveness and Budget-Impact Analysis -- Exercises -- References -- Chapter 12: Additional Pragmatic Topics -- 12.1 Off-Label Drug Use -- 12.2 Adherence and Persistence -- 12.2.1 Definitions -- 12.2.2 Impact of Adherence or Persistence on Costs -- 12.2.3 Adherence and Persistence Estimates: Sources and Use in Budget Impact Analyses -- 12.3 Cost Type -- Exercises -- References -- Chapter 13: Alternative Interventions -- 13.1 Vaccines -- 13.2 Screening and Diagnostic Tests -- 13.3 Surgery.

13.4 Medical Devices -- Exercises -- References -- Chapter 14: Creating Your Own Budget-Impact Analyses Today and Tomorrow -- 14.1 Overview -- 14.2 Budget Impact Versus Cost-Effectiveness -- 14.3 Balancing Methods with Credibility -- 14.4 Closing -- References.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.